Bluebird Bio’s (BLUE) “Buy” Rating Reaffirmed at Goldman Sachs Group Inc.
Several other equities analysts have also commented on BLUE. Maxim Group set a $85.00 price target on Bluebird Bio and gave the stock a buy rating in a research report on Thursday, September 22nd. Leerink Swann reissued an outperform rating and set a $67.00 price target on shares of Bluebird Bio in a research report on Thursday, August 4th. BTIG Research reissued a buy rating and set a $83.00 price target (up from $72.00) on shares of Bluebird Bio in a research report on Saturday. Wedbush reissued an outperform rating and set a $117.00 price target on shares of Bluebird Bio in a research report on Wednesday, August 3rd. Finally, Vetr raised Bluebird Bio from a buy rating to a strong-buy rating and set a $44.44 price target on the stock in a research report on Monday, June 27th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and fourteen have issued a buy rating to the company. Bluebird Bio currently has a consensus rating of Buy and a consensus target price of $91.60.
Shares of Bluebird Bio (NASDAQ:BLUE) traded down 13.29% during trading on Friday, reaching $56.57. 4,144,106 shares of the company’s stock traded hands. The company has a 50 day moving average price of $63.71 and a 200 day moving average price of $50.93. The stock’s market capitalization is $2.10 billion. Bluebird Bio has a 1-year low of $35.37 and a 1-year high of $99.70.
Bluebird Bio (NASDAQ:BLUE) last released its quarterly earnings results on Wednesday, August 3rd. The company reported ($1.59) EPS for the quarter, missing the consensus estimate of ($1.44) by $0.15. The company had revenue of $1.55 million for the quarter, compared to analyst estimates of $2.01 million. Bluebird Bio had a negative return on equity of 24.85% and a negative net margin of 3,512.13%. The business’s revenue was down 68.6% on a year-over-year basis. During the same period last year, the firm posted ($1.57) earnings per share. On average, equities analysts forecast that Bluebird Bio will post ($6.19) EPS for the current fiscal year.
In other news, insider Eric Sullivan sold 416 shares of the company’s stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $67.00, for a total value of $27,872.00. Following the completion of the sale, the insider now owns 5,891 shares in the company, valued at $394,697. The sale was disclosed in a legal filing with the SEC, which is available at this link. 3.50% of the stock is owned by insiders.
Several large investors have recently made changes to their positions in the stock. Seven Eight Capital LLC bought a new stake in shares of Bluebird Bio during the first quarter valued at approximately $108,000. Quantbot Technologies LP increased its stake in shares of Bluebird Bio by 431.3% in the second quarter. Quantbot Technologies LP now owns 2,848 shares of the company’s stock valued at $123,000 after buying an additional 2,312 shares in the last quarter. First Mercantile Trust Co. bought a new stake in shares of Bluebird Bio during the third quarter valued at approximately $129,000. BlackRock Inc. increased its stake in shares of Bluebird Bio by 341.0% in the first quarter. BlackRock Inc. now owns 4,569 shares of the company’s stock valued at $194,000 after buying an additional 3,533 shares in the last quarter. Finally, BNP Paribas Arbitrage SA increased its stake in shares of Bluebird Bio by 110.5% in the third quarter. BNP Paribas Arbitrage SA now owns 3,084 shares of the company’s stock valued at $209,000 after buying an additional 1,619 shares in the last quarter.
About Bluebird Bio
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.